Incyte (INCY) has an average rating of overweight and mean price target of $109.57, according to analysts polled by FactSet.
Price: $103.10, Change: $+2.46, Percent Change: +2.44%
Related Articles
Wire
Mission Produce Fiscal Q2 Adjusted Earnings, Revenue Fall; Shares Drop After Hours
Mission Produce (AVO) reported fiscal Q2 non-GAAP net income late Monday of $0.01 per diluted share, down from $0.12 a year earlier.Three analysts polled by FactSet expected $0.05.Revenue in the three months ended April 30 fell to $290.9 million from $380.3 million a year earlier.Three analysts expected $256.3 million.The board approved a stock repurchase program of up to $100 million over the next 36 months.The company's shares fell 5.9% in after-hours trading.
$AVO
Wire
Mama's Creations Fiscal Q1 Earnings, Revenue Rise
Mama's Creations (MAMA) reported fiscal Q1 earnings late Monday of $0.05 per diluted share, up from $0.03 a year earlier.Analysts polled by FactSet expected $0.03.Revenue in the three months ended April 30 rose to $52.8 million from $35.3 million a year earlier.Analysts expected $51.6 million.The company's shares fell 2.6% in after-hours trading.
$MAMA
Wire
Tango Therapeutics Launches $500 Million Stock Offering
Tango Therapeutics (TNGX) said Monday it is launching $500 million underwritten public offering of common stock.All shares are offered by the company, according to a statement.Tango said it will grant underwriters a 30-day option to purchase up to an additional $75 million of shares.
$TNGX